Brain Trust Accelerator Fund

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

MyAvana, originally known as Madame You, specializes in personalized hair care solutions by integrating artificial intelligence with expert advice. The company offers a mobile application that provides users with a scientific analysis of their hair type and texture. Through this platform, users receive tailored recommendations for hair products and styling techniques that best suit their individual needs. By leveraging data-driven insights, MyAvana aims to empower women to make informed decisions regarding their hair care, enhancing their overall experience and satisfaction.

Chase Therapeutics is an early-stage specialty pharmaceutical company dedicated to developing innovative treatments for brain diseases. The company focuses on creating novel compounds that address both symptomatic relief and disease modification, aiming to enhance the quality of life for individuals affected by central nervous system disorders. Through its research and development efforts, Chase Therapeutics seeks to provide new therapeutic options that improve patient outcomes in the realm of brain health.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Chase Pharmaceuticals (CPC) is engaged in the identification and clinical development of medically improved, commercially promising, treatments for central nervous system (CNS) disease. The Company was incorporated in 2007 to link emerging technical opportunities in the basic neurosciences to the expanding medical needs of those with neuropsychiatric disease. Operations thus focus on selecting product candidates to license-in, adding value by advancing towards global registration, and licensing-out to commercial partners. There success reflects an exceptional ability to select promising drug candidates, intimate knowledge of the development process as well as our ability to devise the most efficient path to regulatory approval. Since inception, CPC has sought to develop novel compounds that could improve the treatment of AD and related neurodegenerative disorders. Alzheimer’s disease constitutes the largest unmet medical need in neuropsychiatry. No emerging therapies have clearly demonstrated the potential to fulfill this medical need. Symptoms include an increasing loss of memory and other cognitive functions later combined with a variety of neuropsychiatric and behavioral disturbances. Progression is relentless, typically leading to death within 10 to 15 years. AD is now recognized as the third leading killer in the U.S. It is estimated that the 37 million afflicted worldwide cost society over $600 billion annually. As the population ages, this burden will rapidly climb to unsustainable levels. Although US sales of Alzheimer’s disease medications last year topped $4.7 billion, none of the current treatments improve symptoms more than marginally. Moreover, tolerability is poor, dose titration prolonged, and dropout rates high. Chase founders have invented and patented a unique combination of proven, currently marketed pharmaceuticals that we believe will benefit the symptomatic treatment of AD.

Satoris is a company focused on the development and commercialization of neurodiagnostic tests aimed at identifying neurological diseases such as Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy. The company is dedicated to creating tests that provide early, accurate, and clinically relevant diagnoses, which can lead to improved patient care and reduced healthcare costs. By prioritizing convenience and affordability, Satoris aims to enhance access to essential diagnostic services for patients facing these neurological conditions.